Specifically, CYP3A43 levels in cancer samples from stage 3 patients were significantly lower than those in samples from stage 1 (p = 0.003) and stage 2 patients (p = 0.02), respectively (Figure 1A). This evidence concerns the gene CYP3A43 and cancer.